BioScrip Will Expand PBM Business Following Chronimed/MIM Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharmacy companies will build upon MIM’s $400 mil. PBM business (ScripSolutions) ahead of the Medicare drug benefit implementation in 2006. Chronimed CEO Blissenbach, who has executive experience from the PBM industry, will become BioScrip CEO following the close of the deal.